Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its...
from NDTV News - Latest https://ift.tt/3hX2lsF
No comments:
Post a Comment